Finding new targets on cancer cells for better multiple myeloma treatments
Identifying cell surface targets for innovative immunotherapy of Multiple Myeloma
['FUNDING_R37'] · H. LEE MOFFITT CANCER CTR & RES INST · NIH-11124225
This research looks for new ways to target multiple myeloma cells to create more effective and lasting immune-based therapies for patients.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | H. LEE MOFFITT CANCER CTR & RES INST (nih funded) |
| Locations | 1 site (TAMPA, UNITED STATES) |
| Trial ID | NIH-11124225 on ClinicalTrials.gov |
What this research studies
Current immune therapies for multiple myeloma, while effective for many, often do not provide long-term remission. This project aims to discover new weak spots, or 'targets,' on multiple myeloma cells that future treatments can attack. Researchers used advanced laboratory techniques, including mass spectrometry and RNA sequencing, on both cancer cell lines and samples from over 900 patients. They then carefully checked these promising targets in samples from patients with relapsed or difficult-to-treat multiple myeloma, as well as in healthy cells. The goal is to identify novel targets that could lead to more durable and effective immunotherapies.
Who could benefit from this research
Good fit: Patients with multiple myeloma, especially those whose disease has returned or is difficult to treat, could potentially benefit from future therapies developed from this research.
Not a fit: Patients without multiple myeloma would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to the development of new, more effective, and longer-lasting immunotherapies for patients with multiple myeloma.
How similar studies have performed: While current immune therapies for multiple myeloma have shown success, this research focuses on identifying new targets to overcome limitations, building on existing knowledge.
Where this research is happening
TAMPA, UNITED STATES
- H. LEE MOFFITT CANCER CTR & RES INST — TAMPA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PERNA, FABIANA — H. LEE MOFFITT CANCER CTR & RES INST
- Study coordinator: PERNA, FABIANA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.